Скачать или смотреть Implementing clinical outcome assessments in a patient-centered endpoint strategy

Register for this webinar: https://xtalks.com/webinars/implement...

For several years, health authorities have been advocating the use of patient-reported outcomes (PROs) to strengthen the value demonstration of new treatments on efficacy and cost-effectiveness.

PROs reflect patients’ subjective symptoms and the impact of a disease and/or treatment on their quality-of-life and are one of four types of clinical outcome assessments (COAs). Other types of COAs include observer, clinician and performance outcomes, which can each be used independently or as composite measures to capture different perspectives on how patients are feeling or functioning.

Yet, identifying COAs that are fit-for-purpose remains challenging. Selecting COAs for clinical trials depends on multiple parameters, including health authorities’ requirements, trial design, population of interest, targeted disease concepts and the COAs’ psychometric performance.

In this webinar, the expert speakers will explain how to identify the most suitable COAs for requirements to enable endpoint strategies and ultimately de-risk trial operations as well as secure regulatory approval.

The speakers will present strategies to facilitate the selection of fit-for-purpose COAs by defining the right questions for appropriate landscape analysis and by searching the appropriate data on COAs.

Mapi Research Trust has integrated information on COAs in three databases for a streamlined selection process. PROINSIGHT describes guidelines, released by health technology assessment authorities and regulatory agencies, on criteria that endpoint measurement tools should meet. PROLABELS shows COA labelling claims granted by FDA and EMA, reflecting competitors’ claims landscape and PRO success stories in the drug approval process. Finally, PROQOLID reports descriptive information on all types of COAs.

Navigating from guidelines and label claims to COA properties, users can easily source COAs with validation data that are recommended by health agencies and/or substantiated by their use in approved labelling claims. Using COAs that are validated for specific contexts of use helps to de-risk trial deployment, optimizes relevant data collection and the overall endpoint strategy success, thus increasing the likelihood of regulatory approval.

https://xtalks.com/webinars/implement...

#ClinicalResearch #CRO #PatientRecruitment #ClinicalOutcomes #Regulatory #eCOA #ClinicalOutcomeAssessment #ClinicalOutcomeAssessments #electronicClinicalOutcomeAssessments #Quality